Dr. Reddy's Laboratories Limited

500124

INE089A01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 05:00:47 2025-12-10 am EST			5-day change	1st Jan Change
1,251.10 ^INR	+0.39%		-2.30%	-9.88%

Dec. 09	Coya Therapeutics Announces Patients Have Been Dosed in the Alstars Trial of Coya 302 for the Treatment of Als	CI
Dec. 08	Immutep Shares Rise After Unit's Deal With Indian Drugmaker's Subsidiary	MT

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Complete GMP Inspection At Its API manufacturing facility (CTO-5)

Published on 05/27/2025 at 07:50 am EDT

S&P Capital IQ

Dr. Reddy's Laboratories Limited

+0.39%

Dr. Reddy's Laboratories Limited announced that the United States Food & Drug Administration (USFDA) completed a GMP inspection at its API manufacturing facility (CTO-5) in Miryalaguda, Telangana, India. The inspection was conducted from 19 May 2025 to 24 May 2025. The company has been issued a Form 483 with 2 observations, which it will address within the stipulated timeline.

Latest news about Dr. Reddy's Laboratories Limited

Dec. 09	Coya Therapeutics Announces Patients Have Been Dosed in the Alstars Trial of Coya 302 for the Treatment of Als	CI
Dec. 08	Immutep Shares Rise After Unit's Deal With Indian Drugmaker's Subsidiary	MT
Dec. 08	Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Monday Trading	MT
Dec. 08	Immutep, Dr. Reddy's Sign Licensing Deal for Cancer Drug Candidate	MT
Dec. 08	Immutep and Dr. Reddy's enters into strategic collaboration for commercialisation of an innovative oncology drug, eftilagimod alfa	RE
Dec. 08	Immutep SAS and Dr. Reddy?s Laboratories SA Enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa	CI
Dec. 08	Dr Reddy's unit enters strategic collaboration with Immutep SAS	RE
Dec. 08	Immutep enters into strategic collaboration with Dr. Reddy's	RE
Dec. 05	Sector Update: Health Care Stocks Lower Late Afternoon	MT
Dec. 05	Sector Update: Health Care Stocks Decline Friday Afternoon	MT
Dec. 05	European Equities Close Mixed in Friday Trading; EU GDP Grows 0.4% in Q3	MT
Dec. 05	Sector Update: Health Care Stocks Rise Pre-Bell Friday	MT
Dec. 05	Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide	MT
Dec. 04	Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs -- 2nd Update	DJ
Dec. 04	Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs -- Update	DJ
Dec. 04	Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide	MT
Dec. 04	Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs	DJ
Dec. 03	Novo Nordisk gears up for December Ozempic launch in India, sources say	RE
Dec. 02	Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
Dec. 02	Aurigene Oncology Limited announces encouraging initial data from 1st two cohorts of phase 1 study of AUR112	RE
Dec. 02	Indian Equities Drop on Tuesday as Profit Booking, Weak Rupee Pressure Markets	MT
Dec. 02	NATCO Pharma Limited Announces Executive Changes	CI
Nov. 26	Algorae Pharmaceuticals signs distribution agreement with Dr. Reddy's Laboratories	RE
Nov. 26	Dr Reddy's unit receives order for tax demand including penalty	RE
Nov. 25	Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading	MT

Chart Dr. Reddy's Laboratories Limited

Duration

Period

500124: Dynamic Chart

Company Profile

Dr. Reddyâs Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Employees

27,811

Sector

Pharmaceuticals

Calendar

Jan. 22 - Q3 2026 Earnings Release (Projected)

More about the company